Özge Atılgan Karakulak and Selin Sinem Erciyas Spoke at the Pharma Biotech Patent Litigation Europe Summit
Our partners Özge Atılgan Karakulak and Selin Sinem Erciyas represented the firm at the Pharma Biotech Patent Litigation Europe Summit, held in Amsterdam on 19–21 January 2026.
At the summit, Özge Atılgan Karakulak spoke in the session “Competition Law Review from the Life Sciences Sector: A Review of Recent Court Decisions,” while Selin Sinem Erciyas contributed to “Preliminary Injunction Review for the Life Sciences Sector.”
The summit brought together leading practitioners to examine the rapidly evolving landscape of cross-border patent litigation in the life sciences sector, with a particular focus on recent developments and landmark rulings of the Unified Patent Court (UPC). The agenda covered key topics including SPCs, PTEs, Bolar exemptions, and ongoing regulatory reforms across Europe and the United States.
In-depth, sector-specific discussions addressed litigation strategies in MedTech, small-molecule, and large-molecule pharmaceuticals, alongside panels on AI patentability, second medical use claims, skinny labels, and competition law in pharma—highlighting the most pressing legal and strategic challenges currently facing the IP and life sciences industries.
